1 Brown, T. J. et al. Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA oncology 2, 1460-1469, doi:10.1001/jamaoncol.2016.1373 (2016).
2 Smith, J. S. et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26, 1338-1345, doi:10.1200/jco.2007.13.9337 (2008).
3 Stummer, W. et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. The Lancet. Oncology 7, 392-401, doi:10.1016/s1470-2045(06)70665-9 (2006).
4 Molinaro, A. M. et al. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA oncology 6, 495-503, doi:10.1001/jamaoncol.2019.6143 (2020).
5 Orringer, D. et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. Journal of neurosurgery 117, 851-859, doi:10.3171/2012.8.Jns12234 (2012).
6 Petrecca, K., Guiot, M. C., Panet-Raymond, V. & Souhami, L. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. Journal of neuro-oncology 111, 19-23, doi:10.1007/s11060-012-0983-4 (2013).
7 Iversen, D. H., Wein, W., Lindseth, F., Unsgård, G. & Reinertsen, I. Automatic Intraoperative Correction of Brain Shift for Accurate Neuronavigation. World neurosurgery 120, e1071-e1078, doi:10.1016/j.wneu.2018.09.012 (2018).
8 Senft, C. et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. The Lancet. Oncology 12, 997-1003, doi:10.1016/s1470-2045(11)70196-6 (2011).
9 Broadbent, B. et al. Shining light on neurosurgery diagnostics using Raman spectroscopy. Journal of neuro-oncology 130, 1-9, doi:10.1007/s11060-016-2223-9 (2016).
10 Orringer, D. A. et al. Rapid intraoperative histology of unprocessed surgical specimens via fibre-laser-based stimulated Raman scattering histology. Nature biomedical engineering 1, doi:10.1038/s41551-016-0027 (2017).
11 Ji, M. et al. Detection of human brain tumor infiltration with quantitative stimulated Raman scattering histology. Science translational medicine 7, 309ra163, doi:10.1126/scitranslmed.aab0195 (2015).
12 Freudiger, C. W. et al. Multicolored stain-free histopathology with coherent Raman imaging. Laboratory investigation; a journal of technical methods and pathology 92, 1492-1502, doi:10.1038/labinvest.2012.109 (2012).
13 Hollon, T. C. et al. Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. Nature medicine 26, 52-58, doi:10.1038/s41591-019-0715-9 (2020).
14 Wen, P. Y. & Kesari, S. Malignant gliomas in adults. The New England journal of medicine 359, 492-507, doi:10.1056/NEJMra0708126 (2008).
15 Earnest, F. t. et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166, 823-827, doi:10.1148/radiology.166.3.2829270 (1988).
16 Dalrymple, S. J. et al. Changes in proliferating cell nuclear antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory. Neurosurgery 35, 1036-1044; discussion 1044-1035, doi:10.1227/00006123-199412000-00004 (1994).
17 Capper, D. et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain pathology (Zurich, Switzerland) 20, 245-254, doi:10.1111/j.1750-3639.2009.00352.x (2010).
18 Camelo-Piragua, S. et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. Journal of neuropathology and experimental neurology 70, 110-115, doi:10.1097/NEN.0b013e31820565f9 (2011).
19 Kurtkaya-Yapicier, O., Scheithauer, B. W., Hebrink, D. & James, C. D. p53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study. Neurosurgery 51, 1246-1254; discussion 1254-1245, doi:10.1097/00006123-200211000-00021 (2002).
20 Lau, D. et al. A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. Journal of neurosurgery 124, 1300-1309, doi:10.3171/2015.5.Jns1577 (2016).
21 Freudiger, C. W. et al. Label-free biomedical imaging with high sensitivity by stimulated Raman scattering histology. Science (New York, N.Y.) 322, 1857-1861, doi:10.1126/science.1165758 (2008).
22 Mitani, A. A., Freer, P. E. & Nelson, K. P. Summary measures of agreement and association between many raters' ordinal classifications. Annals of epidemiology 27, 677-685.e674, doi:10.1016/j.annepidem.2017.09.001 (2017).
23 Nelson, K. P. & Edwards, D. Measures of agreement between many raters for ordinal classifications. Statistics in medicine 34, 3116-3132, doi:10.1002/sim.6546 (2015).
24 Brat, D. J. et al. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta neuropathologica 136, 805-810, doi:10.1007/s00401-018-1913-0 (2018).